Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266864 · ClinicalTrials.gov registry record · Phase 2
Testosterone Replacement Therapy in Chronic Spinal Cord Injury
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00266864: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT00266864 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00266864, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
It has long been recognized that co-morbidity associated with multiple metabolic syndrome, such as adverse body composition, insulin resistance and autonomic nervous system impairment, may lead to significant increase in cardiovascular morbidity and mortality. It is unclear whether the co-morbidity evident in this population are due directly to their immobility or are the result of unfavorable changes in their underlying hormonal milieu. The purpose of this study is to determine the effect of testosterone replacement therapy in hypogonadal males on: body composition, i.e. lean tissue and fat mass, glucose tolerance, resting energy expenditure, autonomic-cardiovascular integrity, muscular strength, psychological assessment
Interventions
- DRUG Testosterone Transdermal System (Androderm 5 mg patch)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2003-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266864
The ClinicalTrials.gov registry entry for NCT00266864 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Testosterone Transdermal System (Androderm 5 mg patch) is the first listed.
NCT00266864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00266864 about?
NCT00266864 is a clinical study titled "Testosterone Replacement Therapy in Chronic Spinal Cord Injury". It has long been recognized that co-morbidity associated with multiple metabolic syndrome, such as adverse body composition, insulin resistance and autonomic nervous system impairment, may lead to significant increase in cardiovascular morbidity and mortality. It is unclear whether the co-morbidity ...
What is the current status of trial NCT00266864?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2003-08. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00266864?
The interventions under investigation include: Testosterone Transdermal System (Androderm 5 mg patch) (DRUG).
Who is sponsoring clinical trial NCT00266864?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.